RxDoctor Payments DataLook up a doctor →

Sherry Denton, NP

Adult Health · Scottsdale, AZNPI 1851726707

Payments from drug & device makers

$23,285in general payments, 2019–2025

Across 581 payments — averaging $40.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$7K
  • Johnson & Johnson$3K
  • Sumitomo Pharma America, Inc.$2K
  • Pfizer$2K
  • Myriad Genetic Laboratories, Inc.$1K
  • AbbVie$909
  • plus $7K from 34 others

What the payments were for

  • Consulting fees$5002%
  • Speaking & faculty fees$2,53511%
  • Food & beverage$20,03986%
  • Education$2121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,285 in reported general payments places this provider in the 95th percentile of 314 adult health providers in Arizona.

See all adult health providers in Arizona

Medicare billing

Part B allowed, 2024
$191,840
Medicare patients
130
Services billed
3,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide238$3,351,453
ErleadaApalutamide140$2,014,625
OrgovyxRelugolix486$1,278,140
NubeqaDarolutamide54$691,335
Abiraterone Acetate15$44,193
Megestrol Acetate24$597
Tamsulosin Hcl31$432
Prednisone30$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$435$3,351,453238 claims
Johnson & JohnsonErleada$3,003$2,014,625140 claims
Sumitomo Pharma America, Inc.Orgovyx$1,859$1,278,140486 claims
BayerNubeqa$839$691,33554 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$500$44,19315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 314 adult health providers in Arizona.

Other adult health in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →